Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AXL inhibition improves BRAF-targeted treatment in melanoma.

Scientific reports - 24 Mar 2022

Nyakas Marta, Fleten Karianne Giller, Haugen Mads Haugland, Engedal Nikolai, Sveen Christina, Farstad Inger Nina, Flørenes Vivi Ann, Prasmickaite Lina, Mælandsmo Gunhild Mari, Seip Kotryna

Abstract excerpt

More than half of metastatic melanoma patients receiving standard therapy fail to achieve a long-term survival due to primary and/or acquired resistance. Tumor cell ability to switch from epithelial to a more aggressive mesenchymal phenotype, attributed with AXLhigh molecular profile in melanoma, has been recently linked to such event, limiting treatment efficacy. In the current study, we investigated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 35332208
DOI: 10.1038/s41598-022-09078-z
PMCID: PMC8948193

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AXL inhibition improves BRAF-targeted treatment in melanoma.PMID 35332208Read ↗

Autophagy- An emerging target for melanoma therapySemantic proximity Read ↗

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsSemantic proximity Read ↗

PROM2 overexpression induces metastatic potential through epithelial‐to‐mesenchymal transition and ferroptosis resistance in human cancersSemantic proximity Read ↗

Role of the pro-survival molecule Bfl-1 in melanoma.Semantic proximity Read ↗

AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma.Semantic proximity Read ↗

Melanin enhances metastatic melanoma colonization by inhibiting ferroptosisSemantic proximity Read ↗

Autophagy, anoikis, ferroptosis, necroptosis, and endoplasmic reticulum stress: Potential applications in melanoma therapySemantic proximity Read ↗

Patient-derived zebrafish xenograft models reveal ferroptosis as a fatal and druggable weakness in metastatic uveal melanomaSemantic proximity Read ↗

Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.Semantic proximity Read ↗

Loss of Ambra1 promotes melanoma growth and invasion.Semantic proximity Read ↗

Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug targetSemantic proximity Read ↗

AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.